Early COVID-Related pandemic impacts and subsequent opioid outcomes among persons receiving medication for opioid use disorder: a secondary data analysis of a Type-3 hybrid trial.
COVID-19
Epidemic-pandemic impacts inventory
Opioid use disorder
Opioids
Journal
Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917
Informations de publication
Date de publication:
13 09 2023
13 09 2023
Historique:
received:
06
12
2022
accepted:
28
08
2023
medline:
15
9
2023
pubmed:
14
9
2023
entrez:
13
9
2023
Statut:
epublish
Résumé
Opioid overdoses have continued to increase since the start of the COVID-19 pandemic. The pathways through which the COVID-19 pandemic has affected trajectories of opioid use and opioid-related problems are largely unknown. Using the Epidemic-Pandemic Impacts Inventory (EPII), a novel instrument that assess pandemic-related impacts across multiple life domains, we tested the hypothesis that COVID-related impacts (on e.g., interpersonal conflict, employment, infection exposure, and emotional health) experienced in the early months of the pandemic would predict changes in opioid use and opioid-related problems at follow-up. This analysis was embedded within a cluster randomized type 3 implementation-effectiveness hybrid trial that had enrolled 188 patients across eight opioid treatments prior to the start of the pandemic. Participants had all been recently inducted on medication for opioid use disorder and were actively receiving treatment. Participants reported on their opioid use and opioid-related problems at baseline and 3-, 6-, and 9-month post-baseline assessments. Between May and August 2020, participants were sent an optional invitation to complete the EPII. One hundred thirty-three respondents completed the EPII and 129 had sufficient data to analyze the EPII and at least one subsequent follow-up. In logistic and zero-inflated negative binomial analyses adjusting for covariates, each endorsed pandemic impact in the interpersonal conflict domain was associated with 67% increased odds of endorsement of any opioid use, and each impact in the employment and infection exposure-domains was associated with 25% and 75% increases in number of endorsed opioid-related problems, respectively. Mitigating the effect of the pandemic on patients' interpersonal relationships and employment, and promoting greater infection control in opioid treatment programs, could be protective against negative opioid-related outcomes. Trial registration The present study describes secondary data analysis on a previously registered clinical trial: clinicaltrials.gov/ct2/show/NCT03931174.
Sections du résumé
BACKGROUND
Opioid overdoses have continued to increase since the start of the COVID-19 pandemic. The pathways through which the COVID-19 pandemic has affected trajectories of opioid use and opioid-related problems are largely unknown. Using the Epidemic-Pandemic Impacts Inventory (EPII), a novel instrument that assess pandemic-related impacts across multiple life domains, we tested the hypothesis that COVID-related impacts (on e.g., interpersonal conflict, employment, infection exposure, and emotional health) experienced in the early months of the pandemic would predict changes in opioid use and opioid-related problems at follow-up.
METHODS
This analysis was embedded within a cluster randomized type 3 implementation-effectiveness hybrid trial that had enrolled 188 patients across eight opioid treatments prior to the start of the pandemic. Participants had all been recently inducted on medication for opioid use disorder and were actively receiving treatment. Participants reported on their opioid use and opioid-related problems at baseline and 3-, 6-, and 9-month post-baseline assessments. Between May and August 2020, participants were sent an optional invitation to complete the EPII.
RESULTS
One hundred thirty-three respondents completed the EPII and 129 had sufficient data to analyze the EPII and at least one subsequent follow-up. In logistic and zero-inflated negative binomial analyses adjusting for covariates, each endorsed pandemic impact in the interpersonal conflict domain was associated with 67% increased odds of endorsement of any opioid use, and each impact in the employment and infection exposure-domains was associated with 25% and 75% increases in number of endorsed opioid-related problems, respectively.
CONCLUSIONS
Mitigating the effect of the pandemic on patients' interpersonal relationships and employment, and promoting greater infection control in opioid treatment programs, could be protective against negative opioid-related outcomes. Trial registration The present study describes secondary data analysis on a previously registered clinical trial: clinicaltrials.gov/ct2/show/NCT03931174.
Identifiants
pubmed: 37705105
doi: 10.1186/s13722-023-00409-7
pii: 10.1186/s13722-023-00409-7
pmc: PMC10500804
doi:
Substances chimiques
Analgesics, Opioid
0
Banques de données
ClinicalTrials.gov
['NCT03931174']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Subventions
Organisme : NIAAA NIH HHS
ID : K01 AA026335
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA046941
Pays : United States
Informations de copyright
© 2023. Evans Medical Foundation, Inc. and BioMed Central Ltd.
Références
Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013–2017. Morb Mortal Wkly Rep. 2018;67(5152):1419–27.
CDC. Underlying causes of death 2021. https://wonder.cdc.gov/Deaths-by-Underlying-Cause.html .
CDC. Drug overdose deaths in the U.S. Top 100,000 Annually 2021. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm .
Binswanger IA, Nowels C, Corsi KF, Glanz J, Long J, Booth RE, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7:3.
doi: 10.1186/1940-0640-7-3
pubmed: 22966409
pmcid: 3414824
Nalven T, Spillane NS, Schick MR. Risk and protective factors for opioid misuse in american indian adolescents. Drug Alcohol Depend. 2020;206:107736.
doi: 10.1016/j.drugalcdep.2019.107736
pubmed: 31765857
Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. The Lancet. 2020;395(10227):912–20.
doi: 10.1016/S0140-6736(20)30460-8
Golberstein E, Wen H, Miller BF. Coronavirus disease 2019 (COVID-19) and mental health for children and adolescents. JAMA Pediatr. 2020;174(9):819–20.
doi: 10.1001/jamapediatrics.2020.1456
pubmed: 32286618
Davis MA, Lin LA, Liu H, Sites BD. Prescription opioid use among adults with mental health disorders in the United States. J Am Board Fam Med. 2017;30(4):407–17.
doi: 10.3122/jabfm.2017.04.170112
pubmed: 28720623
Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analgesia. 2017;125(5):1741–8.
doi: 10.1213/ANE.0000000000002496
Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020;173(1):61–2.
doi: 10.7326/M20-1212
pubmed: 32240293
Humphreys KL, Myint MT, Zeanah CH. Increased risk for family violence during the COVID-19 pandemic. Pediatrics. 2020;146(1): e20200982.
doi: 10.1542/peds.2020-0982
pubmed: 32317306
Mazza M, Marano G, Lai C, Janiri L, Sani G. Danger in danger: interpersonal violence during COVID-19 quarantine. Psychiatry Res. 2020;289:113046.
doi: 10.1016/j.psychres.2020.113046
pubmed: 32387794
pmcid: 7190494
El-Bassel N, Gilbert L, Wu E, Go H, Hill J. Relationship between drug abuse and intimate partner violence: a longitudinal study among women receiving methadone. Am J Public Health. 2005;95(3):465–70.
doi: 10.2105/AJPH.2003.023200
pubmed: 15727978
pmcid: 1449203
Stein MD, Conti MT, Kenney S, Anderson BJ, Flori JN, Risi MM, et al. Adverse childhood experience effects on opioid use initiation, injection drug use, and overdose among persons with opioid use disorder. Drug Alcohol Depend. 2017;179:325–9.
doi: 10.1016/j.drugalcdep.2017.07.007
pubmed: 28841495
pmcid: 5599365
Grasso DJ, Briggs-Gowan MJ, Ford JD, Carter AS. Profiling COVID-related experiences in the United States with the Epidemic-Pandemic Impacts Inventory: linkages to psychosocial functioning. Brain Behav. 2020. https://doi.org/10.1002/brb3.2197 .
doi: 10.1002/brb3.2197
Benishek LA, Dugosh KL, Kirby KC, Matejkowski J, Clements NT, Seymour BL, et al. Prize-based contingency management for the treatment of substance abusers: a meta-analysis. Addiction. 2014;109(9):1426–36.
doi: 10.1111/add.12589
pubmed: 24750232
pmcid: 4203362
Becker SJ, Murphy CM, Hartzler B, Rash CJ, Janssen T, Roosa M, et al. Project MIMIC (maximizing implementation of motivational incentives in clinics): a cluster-randomized type 3 hybrid effectiveness-implementation trial. Addict Sci Clin Pract. 2021;16(1):61.
doi: 10.1186/s13722-021-00268-0
pubmed: 34635178
pmcid: 8505014
Kelly JP, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507–13.
doi: 10.1016/j.pain.2008.01.027
pubmed: 18342447
Sobell LC, Sobell MB. Timeline follow-back. Measuring Alcohol Consumption. 1992:41–72.
Riley BB, Conrad KJ, Bezruczko N, Dennis ML. Relative precision, efficiency and construct validity of different starting and stopping rules for a computerized adaptive test: the GAIN substance problem scale. J Appl Meas. 2007;8(1):48–64.
pubmed: 17215565
pmcid: 5933849
Dennis ML, Titus JC, White MK, Unsicker JI, Hodginks D. Global appraisal of individual needs: administration guide for the GAIN and related measure. Bloomington, IL: Chestnut Health Systems. 2003.
Atkins DC, Baldwin SA, Zheng C, Gallop RJ, Neighbors C. A tutorial on count regression and zero-altered count models for longitudinal substance use data. Psychol Addict Behav. 2013;27(1):166–77.
doi: 10.1037/a0029508
pubmed: 22905895
MR Clairvoyant. 2019. https://blog.clairvoyantsoft.com/correlation-and-collinearity-how-they-can-make-or-break-a-model-9135fbe6936a .
Shover CL, Falasinnu TO, Dwyer CL, Santos NB, Cunningham NJ, Freedman RB, et al. Steep increases in fentanyl-related mortality west of the Mississippi river: recent evidence from county and state surveillance. Drug Alcohol Depend. 2020;216:108314.
doi: 10.1016/j.drugalcdep.2020.108314
pubmed: 33038637
pmcid: 7521591